INPP5F may be a novel, easily assessable biomarker in CLL, because its prognostic significance of INPP5F expression remained detectable in the set of unselected PBMCs, and this may support the clinical feasibility of this biomarker as the analytical workflow may not require separation of B cells as for ZAP70 or laborious assessment of the IGVH mutational status. This evidence concerns the gene INPP5F and B-cell chronic lymphocytic leukemia.